Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris

Kimura, Shigeki; Sugiyama, Tomoyo; Hishikari, Keiichi; Nakagama, Shun; Nakamura, S.; Misawa, Toru; Mizusawa, Masafumi; Hayasaka, Kazumasa; Yamakami, Yosuke; Sagawa, Yuichiro; Kojima, Kensuke; Ohtani, Hirofumi; Hikita, Hiroyuki; Takahashi, Atsushi

doi:10.1016/j.atherosclerosis.2019.11.022

Cited by 12 publications

(19 citation statements)

References 37 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 19 relevant records were further excluded for the reasons given in Figure 1. Finally, 16 cohort studies were obtained for the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28).…”

Section: Literature Searchmentioning

confidence: 99%

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

Ding

Shi

Qian

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Association between plasma pentraxin-3 (PTX-3) and clinical outcomes in patients with coronary artery disease (CAD) remains not fully determined. An updated meta-analysis of cohort studies was performed to systematically evaluate the association.Methods: Cohort studies evaluating the association between plasma PTX-3 and adverse outcomes [mortality and major adverse cardiovascular events (MACEs)] in adults with CAD were identified by systematic search of PubMed, Embase, and Web of Science databases. Only studies with multivariate analysis were included. A random-effects model incorporating the potential intrastudy heterogeneity was used for the meta-analysis.Results: A total of 16 studies including 11,007 patients were included. Pooled results showed that patients with highest level of PTX-3 were independently associated with higher risk of mortality [adjusted risk ratio (RR): 2.09, 95% CI: 1.60 to 2.74, p < 0.001; I2 = 50%] and MACEs (adjusted RR: 1.80, 95% CI: 1.43 to 2.28, p < 0.001; I2 = 49%). Subgroup analyses showed that the associations between PTX-3 and poor prognosis in CAD were consistent in patients with ST-segment elevation myocardial infraction, non-ST-segment elevation acute coronary syndrome, and stable CAD (p < 0.05 for each subgroup). Besides, the association between PTX-3 and increased incidence of mortality and MACEs were consistent in short-term (within 1 year) and long-term (over 1 year) studies and in studies with or without adjustment of C-reactive protein (CRP) (p < 0.05 for each subgroup).Conclusion: Higher plasma PTX-3 is associated with poor prognosis in patients with CAD, which may be independent of the CAD subtype, follow-up durations, and adjustment of CRP.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

Ding

Shi

Qian

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…The imagines of intravascular OCT were performed in accordance with the described methods previously. 8 In summary, OCT images of culprit lesions were obtained by a catheter (Dragonfly™; LightLab Imaging, Inc., Westford, MA, USA) and a frequency-domain OCT system (ILUMIEN OPTIS™; St. Jude Medical/Abbott, St. Paul, MN, USA). offline review workstation (Ilumien Optis, St Jude Medical).…”

Section: Oct Image Acquisitionmentioning

confidence: 99%

“…[3][4][5] Pentraxin-3 (PTX3), produced mainly by dendritic cells, macrophages, and endothelial cells in response to primary inflammatory sti-muli1, was involved in the pathogenesis of atherosclerosis and influenced clinical outcomes. [6][7][8] Optical coherence tomography (OCT), a cross-sectional and high-resolution intravascular imaging technique, allows the acquisition of detailed in vivo images of coronary plaque morphology characteristics, including plaque rupture (PR) and plaque erosion (PE) which are responsible for the majority of acute coronary events. [9][10][11] PCSK9 inhibitor has been reported that it could reduce plaque lipid content and inflammatory index of lipid-core.…”

Section: Introductionmentioning

confidence: 99%

Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

Zhao

Song

Wang

et al. 2021

JIR

View full text Add to dashboard Cite

Background and Aim:The aim of prospective study was to determine the prognostic value of combined measures of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and pentraxin 3 (PTX3) according to the culprit-plaque morphology (plaque rupture versus plaque erosion) in relation to the in patients with acute ST-elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention. Methods: A total of 434 patients with STEMI aged ≥18 years who underwent preintervention OCT imaging of culprit lesions between March 2017 and March 2019 were enrolled. Finally, 235 patients who meet the inclusion criteria were enrolled and the cohort was divided into 3 groups according to PCSK9 and PTX3 levels: group A: PCSK9 < median and Pentraxin 3 (N = 72/30.6%); group B: PCSK9 ≥ median or Pentraxin 3≥ median (N = 91/ 38.7%); group C: PCSK9 ≥ median and Pentraxin 3≥ median (N = 72/30.6%). MACEs were defined as a composite of all-cause death, myocardial infarction (MI) recurrence, and ischemic stroke, revascularization and heart failure. Outcomes: During a median follow-up of 2.01 years, 50 patients has occurred MACE. Two-year MACE was higher in group C (23/31.9%) than in group B (16/17.6%) and group A (11/15.3%) (p = 0.028). There was a correlation between PCSK9 and PTX3 (r = 0.302, p < 0.003). In multivariable analysis adjusted for age, gender, risk factors, and serum indexes, being in group C remained independently associated with an increased risk of MACE (hazard ratio [HR]: 2.90; p = 0.010), and group B tended to have higher MACE (HR: 1.76; p = 0.172) compared with group A. Among patients with plaque erosion by OCT, group C was independently associated with an increased risk of MACE (HR: 9.04; p = 0.048) after fully adjustment. However, the significant association was absence among patients with plaque rupture. Conclusion and Relevance:This study demonstrated the usefulness of combined measures of PCSK9 and PTX3 to enhance risk stratification in patients with STEMI especially among patients with plaque erosion. Patients with elevation of both PCSK9 and PTX3 had a markedly increased risk of MACE.

show abstract

“…A "light based biopsy" using OCT already has several knowledge generating applications e.g. to test novel plaque modifying therapies [11], to identify novel risk markers [12,13] and to determine potential interactions between plaque phenotype and preventative medications [14,15]. Many questions remain to be answered to realise the potential clinical application of guiding personalised risk reduction strategies.…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

A “light based biopsy” for high-risk atherosclerotic plaque

2020

View full text Add to dashboard Cite

Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris

Cited by 12 publications

References 37 publications

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

A “light based biopsy” for high-risk atherosclerotic plaque

Contact Info

Product

Resources

About